Aspire Biopharma's Sublingual Aspirin Shows Twice-Faster Action in Heart Attack Treatment Trial
Key Insights
Aspire Biopharma's sublingual aspirin formulation significantly inhibited serum thromboxane B2 within two minutes, acting approximately twice as fast as chewed aspirin tablets in clinical trials.
The investigational product produced higher and more rapid plasma concentrations of acetylsalicylic acid compared to standard chewed aspirin tablets with statistical significance (p<0.05).
These breakthrough results enable a potential regulatory submission for accelerated FDA approval targeting Q3 2025 for treating acute myocardial infarction.
Aspire Biopharma Holdings (search) has announced breakthrough final results from its clinical trial demonstrating that its sublingual aspirin formulation acts approximately twice as fast as current chewed aspirin tablet recommendations for heart attack treatment. The randomized, crossover bioavailability trial showed the investigational product significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing, a critical timeframe during suspected myocardial infarctions.
Superior Pharmacokinetic Profile Demonstrated
The clinical trial results revealed that Aspire's sublingual aspirin product produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA) compared to chewed uncoated aspirin tablets, with statistical significance (p<0.05). ASA represents the active antiplatelet form of aspirin responsible for therapeutic effects during cardiac emergencies.
TxB2 serves as a biomarker indicating aspirin's effect on platelet aggregation, the clumping process that leads to dangerous blood clots. The rapid inhibition achieved by Aspire's formulation addresses a critical therapeutic window during suspected heart attacks, when clots blocking coronary arteries can cause permanent cardiac muscle damage.
Addressing Significant Medical Need
According to the NIH data cited in the study, acute myocardial infarction represents a major cause of death, affecting nearly 3 million Americans annually and resulting in over one million deaths. The current standard of care involves chewed aspirin tablets, but Aspire's sublingual delivery technology demonstrates superior speed of action in this life-threatening condition.
Safety and Regulatory Pathway
The randomized, crossover bioavailability trial assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational sublingual aspirin product compared to chewed aspirin tablets in healthy adults. Results showed the sublingual formulation was safe and well-tolerated throughout the study period.
Based on these clinical trial results, Aspire plans to review the data with the FDA to enable a potential regulatory submission for accelerated approval. The company has indicated this regulatory pathway is on track for Q3 2025, potentially bringing this faster-acting aspirin formulation to patients experiencing cardiac emergencies.
Technology Platform Implications
Aspire's multi-faceted patent-pending drug delivery technology underlying the sublingual aspirin represents a platform approach that could have broader applications beyond cardiac care. The demonstrated ability to achieve rapid systemic drug absorption through sublingual administration may have implications for other emergency medical situations requiring immediate therapeutic intervention.